Lexeo Therapeutics and Abivax seek Nasdaq listings in shrinking pre-Thanksgiving window for biotech IPOs

Kyle LaHucik

Senior Reporter

Andrew Dunn

Senior Biopharma Correspondent

The gene therapy startup Lexeo Therapeutics and inflammatory disease biotech Abivax filed paperwork to go public Friday afternoon, as the pre-Thanksgiving IPO window shrinks and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lexeo Therapeutics and Abivax seek Nasdaq listings in shrinking pre-Thanksgiving window for biotech IPOs

Kyle LaHucik

Senior Reporter

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Are programs with compounded GLP-1s safe for your population?

Lex­eo Ther­a­peu­tics and Abi­vax seek Nas­daq list­ings in shrink­ing pre-Thanks­giv­ing win­dow for biotech IPOs

Senior Reporter

Senior Biopharma Correspondent

Sign up to read this article for free.

Lexeo Therapeutics and Abivax seek Nasdaq listings in shrinking pre-Thanksgiving window for biotech IPOs